Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?

As evidenced by the recent approvals of Removab (EU, Trion Pharma) in 2009 and of Blincyto (US, Amgen) in 2014, the high potential of bispecific antibodies in the field of immuno-oncology is eliciting a renewed interest from pharmaceutical companies. Supported by rapid advances in antibody engineeri...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Joanie Del Bano, Patrick Chames, Daniel Baty, Brigitte Kerfelec
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2015-12-01
Edice:	Antibodies
Témata:	bispecific antibody cancer immunotherapy NK cells T-cells immune effector cells immuno-checkpoint
On-line přístup:	http://www.mdpi.com/2073-4468/5/1/1
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!